📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Laurus Labs Receives NCLT Approval for Subsidiary Restructuring and Amalgamation
Laurus Labs has received approval from the NCLT Amravati Bench for its Composite Scheme of Arrangement involving two wholly-owned subsidiaries. The plan involves demerging Unit-1 of Laurus Synthesis Private Limited (LSPL) into Sriam Labs and merging the remaining LSPL business directly into Laurus Labs Limited. The NCLT has dispensed with meetings for shareholders and creditors of the parent company, significantly streamlining the regulatory path. Meetings for unsecured creditors of the subsidiaries are now scheduled for April 06, 2026, to move the process toward final completion.
Key Highlights
NCLT Amravati Bench allowed the First Motion Application for the scheme on February 24, 2026
Unit-1 of Laurus Synthesis Private Limited to be demerged and merged into Sriam Labs Private Limited
Remaining business undertakings of LSPL to be amalgamated with the parent company, Laurus Labs Limited
Meetings of Equity Shareholders and all Creditors of the parent company (Laurus Labs) have been dispensed with
Meetings for Unsecured Creditors of LSPL and Sriam Labs are directed to be held on April 06, 2026
💼 Action for Investors
Investors should view this as a positive step toward corporate simplification and operational efficiency. Monitor the outcome of the unsecured creditor meetings in April as the final steps toward full integration of the CDMO business.
Laurus Labs Q3 FY26 Revenue Up 26% to ₹1,778 Cr; EBITDA Margins Expand to 27%
Laurus Labs reported a strong Q3 FY26 with revenue growing 26% YoY to ₹1,778 crores, driven by a 37% surge in the generics division. Profitability showed significant improvement as EBITDA margins expanded to 27% and PAT for the 9-month period jumped 388% to ₹610 crores. The company is aggressively investing in high-growth areas like peptides and ADCs, with a planned CAPEX of ₹1,000 crores for both FY26 and FY27. Management maintains a healthy balance sheet with a net debt-to-EBITDA ratio of 1.2x.
Key Highlights
Q3 FY26 Revenue grew 26% YoY to ₹1,778 crores with Gross Margins expanding to 60.9%
Generics division revenue rose 37% to ₹1,327 crores, fueled by ARV volumes and new launches
CDMO segment recorded over 50% growth in the 9-month period, despite a phased Q3 performance of ₹408 crores
Planned CAPEX of ₹1,000 crores for FY26 and FY27 to scale peptide and ADC capabilities
9-month PAT surged 388% YoY to ₹610 crores, with ROCE improving to 18.5%
💼 Action for Investors
Investors should view the margin expansion and strong CDMO growth as positive indicators of a structural shift in the business mix. Monitor the execution of the new fermentation and ADC facilities for long-term value creation.
Laurus Labs Q3 Net Profit Surges 174% YoY to ₹252 Cr; EBITDA Margins Expand to 27.3%
Laurus Labs reported a robust Q3 FY26 with revenue growing 26% YoY to ₹1,778 crore, driven by a 37% surge in the Generics division. Profitability saw a massive jump, with Net Profit increasing 174% to ₹252 crore and EBITDA margins expanding by 720 bps to 27.3%. For the 9M FY26 period, the company crossed the ₹5,000 crore revenue mark with a 104% growth in EBITDA. While the CDMO segment showed 43% growth in the 9M period, the Bio segment faced temporary scale-up challenges with a 9% decline.
Key Highlights
Q3 FY26 Net Profit grew 174% YoY to ₹252 Cr, while 9M FY26 Net Profit surged 388% to ₹610 Cr
EBITDA margins improved significantly to 27.3% in Q3, up from 20.1% in the previous year
9M FY26 Revenues reached ₹5,001 Cr (+30% YoY), supported by strong performance in CDMO and Generics
Net Debt leverage improved to 1.2x EBITDA despite ongoing CAPEX at 15% of sales
Generics division revenue grew 37% in Q3, led by higher ARV volumes and developed market offtake
💼 Action for Investors
Investors should focus on the significant margin expansion and debt reduction as signs of high operational efficiency. The strong 9M performance and the company's strategic shift toward high-value CDMO projects and Peptides/ADC platforms provide a positive long-term outlook.
Laurus Labs Q3 FY26 Net Profit Surges 174% to ₹252 Cr; 9M Revenue Hits ₹5,001 Cr
Laurus Labs reported a robust performance for 9M FY26, with revenues growing 30% YoY to ₹5,001 crore and net profit jumping 388% to ₹610 crore. The growth was primarily driven by the CDMO division, which saw 43% growth in the nine-month period, and strong execution in the Generics segment. EBITDA margins expanded significantly to 26.1% for 9M FY26, up from 16.6% in the previous year, aided by a better product mix and operational leverage. The company continues its aggressive CAPEX plan, investing ₹735 crore in 9M FY26 towards new technologies like peptides and gene therapy.
Key Highlights
9M FY26 Revenue grew 30% YoY to ₹5,001 Cr, while Net Profit skyrocketed 388% to ₹610 Cr.
EBITDA margins improved by 950 bps to 26.1% in 9M FY26 due to better product mix and scale.
CDMO Small Molecules segment grew 50% in 9M FY26, despite a muted Q3 due to campaign timing.
Net Debt-to-EBITDA significantly reduced to 1.2x from 3.1x a year ago, showing improved financial health.
Cumulative CAPEX for FY22-26 is projected at ~₹3,900 Cr, focusing on high-growth areas like Peptides and ADCs.
💼 Action for Investors
Investors should take note of the significant margin expansion and the sharp reduction in leverage, which indicate a strong operational turnaround. The company's transition towards high-value CDMO projects and new modalities like gene therapy provides a positive long-term outlook.
Laurus Labs Q3 FY26 Net Profit Surges 172% YoY to ₹251.66 Cr; Revenue Up 25.7%
Laurus Labs reported a robust performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 25.7% YoY to ₹1,778.29 crore. Net profit for the quarter witnessed a massive jump of 172.6% YoY, reaching ₹251.66 crore compared to ₹92.30 crore in the same period last year. The nine-month profit for FY26 also showed significant improvement, rising to ₹609.65 crore from ₹124.65 crore YoY. During the quarter, the company also completed strategic investments in Laurus Bio (₹35 crore) and a joint venture with KRKA Pharma (₹49 crore).
Key Highlights
Consolidated Revenue from operations increased by 25.7% YoY to ₹1,778.29 crore in Q3 FY26.
Net Profit after tax surged by 172.6% YoY to ₹251.66 crore for the quarter.
Basic Earnings Per Share (EPS) improved significantly to ₹4.67 from ₹1.71 in the previous year's quarter.
Company invested ₹49 crore for a 49% stake in KRKA Pharma Private Limited joint venture during the quarter.
Nine-month total income reached ₹5,044.48 crore, a substantial increase from ₹3,850.19 crore in the prior year period.
💼 Action for Investors
The strong recovery in both top-line and bottom-line figures suggests a significant turnaround in operational efficiency and market demand. Investors should maintain a positive outlook while monitoring the progress of the pending NCLT approval for the internal demerger and merger scheme.
Laurus Labs Invests ₹49 Crore in KRKA Pharma JV via Rights Issue
Laurus Labs Limited has completed an investment of INR 490 million in its joint venture, KRKA Pharma Private Limited. The company acquired 49,000,000 equity shares at a face value of INR 10 per share through a rights issue. This transaction follows the initial proposal announced on July 25, 2025. The investment demonstrates Laurus Labs' commitment to strengthening its strategic partnership and operational footprint within the JV.
Key Highlights
Invested INR 490,000,000 (₹49 Crores) in KRKA Pharma Private Limited
Acquired 49,000,000 equity shares at a face value of ₹10 each
Investment executed via a rights issue to maintain or increase stake in the JV
Follow-up to the regulatory disclosure originally made in July 2025
💼 Action for Investors
Investors should view this as a strategic move to bolster the company's joint venture capabilities. Monitor future earnings reports for the operational performance and contribution of KRKA Pharma to the consolidated bottom line.
Laurus Labs Invests ₹49 Crore in KRKA Pharma JV via Rights Issue
Laurus Labs has completed an investment of ₹490 million (₹49 crore) in its joint venture, KRKA Pharma Private Limited. The company acquired 49 million equity shares at a face value of ₹10 each through a rights issue. This transaction follows the initial proposal announced on July 25, 2025. The capital infusion is aimed at strengthening the joint venture's operations and supporting its strategic objectives.
Key Highlights
Invested INR 490 million (₹49 crore) in KRKA Pharma Private Limited
Acquired 49 million equity shares at a face value of ₹10 per share
The investment was executed through a rights issue mechanism
KRKA Pharma is an existing joint venture of Laurus Labs
💼 Action for Investors
Investors should view this as a strategic commitment to the company's joint venture operations and monitor the JV's future contribution to the consolidated bottom line.